Advanced search×

Effect of spinal cord stimulation for chronic complex regional pain syndrome Type I: five-year final follow-up of patients in a randomized controlled trial.

Marius A MA Kemler, Henrica C W HC de Vet, Gerard A M GA Barendse, Frans A J M FA van den Wildenberg, and Maarten M van Kleef

J Neurosurg 108(2):292-8 (2008) PMID 18240925

Chronic complex regional pain syndrome-Type I (CRPS-I) is a painful, disabling disorder for which no treatment with proven effect is available. In the present randomized controlled trial, the authors assessed the effectiveness of spinal cord stimulation (SCS) in reducing pain due to CRPS-I at the 5-year follow-up.

DOI: 10.3171/JNS/2008/108/2/0292
Version: za2963e q8zaf q8zb8 q8zca q8zde q8ze8 q8zf1 q8zg2

Similar articles you may find interesting…

  1. Quantum Mechanics in symmetry language
    Houri Ziaeepour

    arXiv:1305.4349 [quant-ph] 19 May 2013

    We consider symmetry as a foundational concept in quantum mechanics and Rewrite quantum mechanics and measurement axioms in this description. We argue That issues related to measurements and physical reality of states can be Better understood in this view. In particular, the abstract concept of symm...
    View PDF
  2. Syntheses, Structures, and Magnetic Properties of Acetato- and Diphenolato-Bridged 3d-4f Binuclear Complexes [M(3-MeOsaltn)(MeOH)x(ac)Ln(hfa...
    Masaaki Towatari, Koshiro Nishi, and Jerzy Mrozinski

    Inorg Chem (2013) PMID 23646986

    A series of 3d-4f binuclear complexes, [M(3-MeOsaltn)(MeOH)x(ac)Ln(hfac)2] (x = 0 for M = Cu(II), Zn(II); x = 1 for M = Co(II), Ni(II); Ln = Gd(III), Tb(III), Dy(III), La(III)), have been synthesized and characterized, where 3-MeOsaltn, ac, and hfac denote N,N'-bis(3-methoxy-2-oxyben...
  3. Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron.
    M Pavesi, N Devlin, and Ia Odeyemi

    J Med Econ (2013) PMID 23647446

    In modified ITT analyses, mirabegron 50mg was superior to tolterodine 4mg in changes from baseline utilities after 12 weeks (p<0.05). EQ-VA...